Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications

Expert Review of Pharmacoeconomics & Outcomes Research
Diane McGinnAlan Haycox

Abstract

To assess the impact of a range of national and regional initiatives introduced in the North Lancashire Teaching Primary Care Trust (NLTPCT) since 2004 to enhance the quality and efficiency of prescribing proton pump inhibitors (PPIs), statins and ezetimibe. In addition, to suggest additional measures that could be introduced in NLTPCT to further enhance the quality and efficiency of prescribing based on initiatives in other European countries. A before-and-after observational study was undertaken on the utilization and expenditure of prescriptions dispensed in ambulatory care in NLTPCT from 2004 to 2007. Utilization was assessed using 'defined daily doses' (DDDs) and 'DDDs/1000 inhabitants per day' and compared over the study period. Reimbursed expenditure was assessed in terms of overall expenditure, expenditure/DDD, as well as expenditure/1000 inhabitants per year. The combination of measures and initiatives enhanced the utilization of generic PPIs. International Nonproprietary Name (INN) prescribing of omeprazole reached 98% of all omeprazole by 2007. The measures also resulted in limited utilization of esomeprazole and lowered reimbursed expenditure/DDD of generic omeprazole to GB pound0.13 by 2007. This was 87% below 2004...Continue Reading

References

Mar 19, 1994·BMJ : British Medical Journal·J Gilley
Feb 22, 2000·The Medical Journal of Australia·P I PillansV Overland
Mar 7, 2001·BMJ : British Medical Journal·S Barton
Feb 14, 2004·BMJ : British Medical Journal·Tom WalleyUNKNOWN EuroMedStat group
May 27, 2004·Health Affairs·Peter C Smith, Nick York
Oct 2, 2004·The New England Journal of Medicine·Martin Roland
Sep 16, 2005·Applied Health Economics and Health Policy·Anne R MasonJonathan Cooke
Jul 28, 2006·The New England Journal of Medicine·Tim DoranMartin Roland
Nov 25, 2006·BMJ : British Medical Journal·Ann BarrettRichard D Smith
Dec 28, 2006·JAMA : the Journal of the American Medical Association·Yu-Xiao YangDavid C Metz
Jan 30, 2007·Current Medical Research and Opinion·Panos Kanavos
May 19, 2007·The American Journal of Gastroenterology·Jennifer LeonardPaul Moayyedi
Jan 5, 2008·BMJ : British Medical Journal·Ian Forgacs, Aathavan Loganayagam
Feb 27, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Kiranbir JosanFinlay A McAlister
Apr 1, 2008·The New England Journal of Medicine·John J P KasteleinUNKNOWN ENHANCE Investigators
Apr 1, 2008·The New England Journal of Medicine·B Greg Brown, Allen J Taylor
Apr 16, 2008·QJM : Monthly Journal of the Association of Physicians·M N ChoudhryH M Ziglam
Apr 18, 2009·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanLars L Gustafsson
Apr 18, 2009·Basic & Clinical Pharmacology & Toxicology·Andreza Fabro de BemJoão Batista Teixeira Rocha
Apr 18, 2009·Basic & Clinical Pharmacology & Toxicology·Grzegorz Raszewski, Rafał Filip
Aug 21, 2009·International Journal of Clinical Practice·C NormanB Wettermark
Oct 6, 2009·Applied Health Economics and Health Policy·Björn WettermarkFlora M Haaijer-Ruskamp
Oct 13, 2009·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanPeter Wieninger
Nov 28, 2009·Expert Review of Pharmacoeconomics & Outcomes Research·Anna ComaAlan Haycox
Dec 30, 2009·Applied Health Economics and Health Policy·Catherine SermetJean-Pierre Reynier
Aug 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanPeter Wieninger
Dec 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·A Aleksander AraszkiewiczAlan Haycox
Aug 14, 2010·BMJ : British Medical Journal·Martin Duerden

❮ Previous
Next ❯

Citations

Dec 4, 2013·European Journal of Clinical Pharmacology·R Fernández UrrusunoB Pascual de la Pisa
Dec 18, 2012·Cardiovascular Drugs and Therapy·Steven Simoens, Peter R Sinnaeve
Nov 21, 2012·BMC Health Services Research·Caitriona CahirKathleen Bennett
Aug 15, 2013·BMC Medicine·Brian GodmanLars L Gustafsson
May 7, 2013·Applied Health Economics and Health Policy·Su-Yeon YuJin-Hyun Kim
Dec 19, 2013·Journal of Comparative Effectiveness Research·Andrew MartinMarion Bennie
Jun 12, 2013·Applied Health Economics and Health Policy·Brian GodmanLars L Gustafsson
Jul 13, 2013·Applied Health Economics and Health Policy·Pieter DylstSteven Simoens
Dec 29, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·L P ThaiA I Vitry
Aug 13, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Luka VončinaLars L Gustafsson
Nov 29, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Vanda Markovic-PekovicLars L Gustafsson
Feb 14, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Pieter DylstSteven Simoens
Feb 14, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Jessica FraeymanPhilippe Beutels
Dec 16, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanLars L Gustafsson
Dec 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Anna BucsicsRickard E Malmström
Apr 25, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Pieter DylstSteven Simoens
Oct 24, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanIlse Truter
Jan 28, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Mohammed AbuelkhairLars L Gustafsson
Jan 28, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Marion BennieStephen Campbell
Jun 16, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Kristina GaruolieneAlan Haycox
Apr 14, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanPeter Wieninger
Mar 1, 2011·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanAlan Haycox
Jul 8, 2015·Basic & Clinical Pharmacology & Toxicology·Elisabetta PoluzziFabrizio De Ponti
Mar 19, 2011·Basic & Clinical Pharmacology & Toxicology·Lars L GustafssonUNKNOWN Regional Drug Expert Consortium
Apr 6, 2013·Pharmacoepidemiology and Drug Safety·Susan E TettNadia Barozzi
Apr 21, 2016·Journal of Comparative Effectiveness Research·Onyinye Onyeka AkunneJoseph Fadare
Oct 24, 2014·Frontiers in Pharmacology·James C MoonRickard E Malmström
Aug 12, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Loc Phuoc ThaiJohn Robert Moss
Jul 10, 2021·Journal of Comparative Effectiveness Research·Brian GodmanJohanna C Meyer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.